NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced that it will hold a conference call on May 12, 2022, at 4:30 PM Eastern Time to discuss its financial results for the second quarter of fiscal 2022, which ended on March 31, 2022. The company specializes in developing minimally invasive solutions for neurological disorders such as epilepsy and Parkinson's disease. NeuroOne's technology aims to improve patient outcomes while potentially lowering hospitalizations and costs.
- Focus on minimizing invasiveness in treatments for neurological disorders.
- Development of technologies that could reduce hospitalizations and costs.
- None.
EDEN PRAIRIE, Minn., May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time.
Conference Call and Webcast Information:
May 12, 2022 – 4:30 PM Eastern Time
Participant Dial-In:
877-407-8293 / +1 201-689-8349
Live Webcast:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=MBrdTO6j
Phone Replay:
877-660-6853 / +1 201-612-7415, Access ID: 13729644; available through May 26, 2022
Webcast Replay:
Available for 12 months
About NeuroOne® Medical Technologies Corporation
NeuroOne is a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. These solutions include electrodes that have the potential to reduce the number of hospitalizations, surgical procedures and cost while improving patient outcomes due to their potential for offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. A combination recording and RF ablation technology is currently under development. In addition, NeuroOne is currently testing its electrodes for long term stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning. Visit n1mtc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-report-second-quarter-fiscal-year-2022-financial-results-on-may-12-301538336.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
When will NeuroOne release its second quarter fiscal 2022 financial results?
What is the focus of NeuroOne Medical Technologies Corporation?
What technologies is NeuroOne working on?
How can I join the NeuroOne conference call?
